JP2003512841A - ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物 - Google Patents

ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物

Info

Publication number
JP2003512841A
JP2003512841A JP2001533989A JP2001533989A JP2003512841A JP 2003512841 A JP2003512841 A JP 2003512841A JP 2001533989 A JP2001533989 A JP 2001533989A JP 2001533989 A JP2001533989 A JP 2001533989A JP 2003512841 A JP2003512841 A JP 2003512841A
Authority
JP
Japan
Prior art keywords
seq
amino acids
fgf
polypeptide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001533989A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003512841A5 (enExample
Inventor
信行 伊藤
ダブリュー． マイケル カバナフ，
Original Assignee
カイロン コーポレイション
京都大学長
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション, 京都大学長 filed Critical カイロン コーポレイション
Publication of JP2003512841A publication Critical patent/JP2003512841A/ja
Publication of JP2003512841A5 publication Critical patent/JP2003512841A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001533989A 1999-10-22 2000-10-20 ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物 Pending JP2003512841A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16116299P 1999-10-22 1999-10-22
US60/161,162 1999-10-22
US18785600P 2000-03-08 2000-03-08
US60/187,856 2000-03-08
PCT/US2000/029237 WO2001031008A2 (en) 1999-10-22 2000-10-20 Human and rat fgf-20 genes and gene expression products

Publications (2)

Publication Number Publication Date
JP2003512841A true JP2003512841A (ja) 2003-04-08
JP2003512841A5 JP2003512841A5 (enExample) 2007-12-06

Family

ID=26857561

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001533989A Pending JP2003512841A (ja) 1999-10-22 2000-10-20 ヒトおよびラットｆｇｆ−２０遺伝子および遺伝子発現産物

Country Status (5)

Country Link
EP (1) EP1224283A2 (enExample)
JP (1) JP2003512841A (enExample)
AU (1) AU1101901A (enExample)
CA (1) CA2388637A1 (enExample)
WO (1) WO2001031008A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056885B1 (en) 1999-07-27 2006-06-06 Curagen Corporation Fibroblast growth factor and nucleic acids encoding same
US7253266B2 (en) 1999-07-27 2007-08-07 Curagen Corporation Polypeptides of FGF-CX
WO2001068854A2 (en) * 2000-03-13 2001-09-20 Amgen, Inc. Fibroblast growth factor-like molecules and uses thereof
GB2365869A (en) * 2000-05-30 2002-02-27 Smithkline Beecham Corp SbgFGF-9a polynucleotides and polypeptides
AU2001262934A1 (en) * 2000-06-01 2001-12-11 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
JP2004502418A (ja) * 2000-07-03 2004-01-29 キュラジェン　コーポレイション 新規の線維芽細胞増殖因子およびそれをコードする核酸
US6982250B2 (en) 2000-11-06 2006-01-03 Curagen Corporation Methods of prevention and treatment of inflammatory bowel disease
US7189693B2 (en) 2000-11-06 2007-03-13 Curagen Corporation Treatment of inflammatory bowel disease using fibroblast growth factor CX polypeptides
US20020151496A1 (en) * 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
JP2005500035A (ja) * 2001-06-15 2005-01-06 キュラジェン コーポレイション 新規線維芽細胞成長因子およびそれをコード化する核酸
WO2004105787A1 (en) * 2003-05-28 2004-12-09 The University Of Kyoto Methods of using combinations of egf-2 and egf-20 to treat central nervous system disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007595A2 (en) * 1999-07-27 2001-02-01 Curagen Corporation Novel fibroblast growth factor and nucleic acids encoding same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367375A1 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007595A2 (en) * 1999-07-27 2001-02-01 Curagen Corporation Novel fibroblast growth factor and nucleic acids encoding same

Also Published As

Publication number Publication date
CA2388637A1 (en) 2001-05-03
WO2001031008A2 (en) 2001-05-03
EP1224283A2 (en) 2002-07-24
AU1101901A (en) 2001-05-08
WO2001031008A3 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
US6716626B1 (en) Human FGF-21 nucleic acids
EP1232264B1 (en) Human fgf-21 gene and gene expression products
US6797695B1 (en) Human FGF-20 gene and gene expression products
EP2075255A1 (en) Human FGF-23 gene and gene expression products
US20030105302A1 (en) Human FGF-23 gene and gene expression products
US20030059431A1 (en) Prostatic growth factor
EP1224283A2 (en) Human and rat fgf-20 genes and gene expression products
US20100130417A1 (en) Transforming growth factor alpha hii
EP0910569A1 (en) Extracellular/epidermal growth factor-like protein
US20030113869A1 (en) Human FGF gene and gene expression products
WO2000056890A1 (en) Human fgf gene and gene expression products
US6852506B1 (en) Extracellular/epidermal growth factor-like protein
US7393832B2 (en) Extracellular/epidermal growth factor like protein
HK1112939A (en) Transforming growth factor alpha hii
CN101298613A (zh) 转化生长因子α-HII
HK1123827A (en) Transforming growth factor alpha hii

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101116